Table 2.

Monoclonal antibodies against IGF1R.

Agent			Ongoing Trials*	Toxicities
AMG 479 Amgen, Thousand Oaks, CA	ganitumab	Fully human monoclonal IgG1	EWS, DSRCT, Ovarian Carcinoma, CRC, NSCLC Pancreatic carcinoma (Phase III)	Thrombocytopenia Hyperglycemia Neutralizing antibodies
RG1507 Roche, Basel, Switzerland		Fully human monoclonal IgG1	Development discontinued	Hyperglycemia Lymphopenia CVA
IMC-A12 ImClone, New York, NY	cixutumumab	Fully human monoclonal IgG1	ACC, thymic carcinoma, SCLC, soft tissue sarcomas, osteosarcoma, EWS, HCC, breast cancer, head and neck carcinoma, prostate cancer, hepatocellular carcinoma, islet cell cancer, pancreatic cancer	Hyperglycemia Anemia Infusion reaction
MK-0646 Merck, Whitehouse Station, NJ	dalotuzumab	Humanized mouse monoclonal IgG1	NSCLC, SCLC, CRC, Pancreatic carcinoma, breast cancer, neuroendocrine tumors	Thrombocytopenia GI bleeding Pneumonitis Increased transaminases
CP-751871 Pfizer, New york, NY	figitumumab	Fully human monoclonal IgG2	CRC, NSCLC, SCLC, breast cancer Phase III (lung cancer) terminated due to lack of benefit	Hyperglycemia Anemia Cholestasis Hyperuricemia
SCH717454 Schering-Plough, Kenilworth, NJ	robatumumab	Fully human monoclonal IgG1	CRC, EWS, osteosarcoma
AVE1642 Sanofi-Aventis, Paris, France		Humanized mouse monoclonal IgG1	Breast cancer, multiple myeloma, hepatocellular carcinoma	Hyperglycemia Hypersensitivity

Abbreviations: EWS, Ewing’s Sarcoma; DSRCT, desmoplastic small round cell tumor ; CRC, colorectal carcinoma; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; ACC, adrenocortical carcinoma; HCC, hepatocellular carcinoma; CVA, cerebral vascular accident.

^*Clinicaltrials.gov